Prevalence of the internalization-associated gene prtF1 in a bacterial population of Streptococcus pyogenes isolated from children with acute pharyngotonsillitis before and after antibiotic therapy

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
C CocuzzaR Mattina

Abstract

The prevalence of the internalization-associated prtF1 gene was studied in 837 isolates of Streptococcus pyogenes obtained from 713 pediatric patients presenting with acute pharyngotonsillitis before and after antibiotic therapy. Its association with macrolide resistance and with bacteriological treatment failure was determined. The bacterial population isolated from baseline pharyngeal swabs showed an overall prtF1 positivity rate of 33%. A higher prtF1 positivity was found among erythromycin-resistant strains (45%) showing, however, marked differences between the inducible (iMLS), constitutive (cMLS), and efflux pump (M) resistance phenotypes. The prevalence was statistically higher (p < 0.001) in strains belonging to iMLS (84%) and cMLS (67%) phenotypes as compared to the M phenotype (15%). Interestingly, the prevalence of the prtF1 gene was significantly lower (p = 0.04) in strains belonging to M resistance phenotype as compared to erythromycin-susceptible strains (28%). Failed bacterial eradication was demonstrated in 124 patients. The prtF1 positivity rate remained unchanged in strains isolated before and after therapy in patients treated with macrolides (9/54). On the other hand, the positivity rate for the prtF1 gene wa...Continue Reading

References

Jun 1, 1978·Antimicrobial Agents and Chemotherapy·T NishiuraM Kono
Jan 30, 1992·The New England Journal of Medicine·H SeppäläT Klaukka
Apr 1, 1990·The Journal of Antimicrobial Chemotherapy·G PhillipsN Young
Jan 1, 1987·The Pediatric Infectious Disease Journal·H C Dillon
Jul 1, 1985·The Journal of Antimicrobial Chemotherapy·J Duval
Dec 1, 1993·The Journal of Antimicrobial Chemotherapy·H SeppäläP Huovinen
Jul 17, 2001·Lancet·A Podbielski, B Kreikemeyer

❮ Previous
Next ❯

Citations

Jun 19, 2010·International Journal of Pediatric Otorhinolaryngology·Gianluca AveronoPaolo Aluffi
Aug 22, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y TakayamaT Akahoshi
Jun 3, 2021·Journal of Clinical Medicine·Gilbert DondersWerner Mendling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.